Acumen Pharmaceuticals, Inc.
ABOS
$0.98
-$0.008-0.81%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 122.67% | 90.70% | 113.87% | 42.88% | 281.07% |
| Gross Profit | -122.67% | -90.70% | -113.87% | -42.88% | -281.07% |
| SG&A Expenses | -3.18% | 3.25% | 11.58% | 20.42% | 48.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 114.20% | 101.17% | 80.89% | 35.32% | 29.74% |
| Operating Income | -114.20% | -101.17% | -80.89% | -35.32% | -29.74% |
| Income Before Tax | -125.22% | -129.72% | -76.89% | -31.54% | -28.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -125.22% | -129.72% | -76.89% | -31.54% | -28.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -125.22% | -129.72% | -76.89% | -31.54% | -28.22% |
| EBIT | -114.20% | -101.17% | -80.89% | -35.32% | -29.74% |
| EBITDA | -114.34% | -101.23% | -80.97% | -35.34% | -29.72% |
| EPS Basic | -117.44% | -107.37% | -20.78% | 9.76% | 9.51% |
| Normalized Basic EPS | -117.50% | -107.37% | -20.75% | 9.81% | 13.40% |
| EPS Diluted | -117.44% | -107.37% | -20.78% | 9.76% | 10.79% |
| Normalized Diluted EPS | -117.50% | -107.37% | -20.75% | 9.81% | 13.40% |
| Average Basic Shares Outstanding | 3.56% | 10.79% | 46.45% | 45.79% | 41.72% |
| Average Diluted Shares Outstanding | 3.56% | 10.79% | 46.45% | 45.79% | 41.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
